Biotech: Page 21
-
Permission granted by Basecamp Research
AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines
The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.
By Gwendolyn Wu • Oct. 9, 2024 -
Permission granted by City Therapeutics
Startup led by John Maraganore raises $135M to build ‘future of RNAi’
“The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
By Ned Pagliarulo • Oct. 8, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Permission granted by Intellia Therapeutics
Intellia starts late-stage test of CRISPR therapy for rare swelling disease
The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.
By Ned Pagliarulo • Oct. 7, 2024 -
Permission granted by Judo Bio
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
By Gwendolyn Wu • Oct. 7, 2024 -
Courtesy of Editas Medicine
Editas trades Vertex fees for upfront cash in DRI deal
The gene editing company is selling to DRI Healthcare Trust future license fees that are owed to it under an agreement with Vertex last year.
By Delilah Alvarado • Oct. 4, 2024 -
Getty Images
Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
By BioPharma Dive staff • Oct. 4, 2024 -
Getty Images
An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped?
An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under scrutiny.
By Meagan Parrish • Updated Oct. 7, 2024 -
Getty Images
With $115M more, Triveni accelerates immune drug work
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.
By Gwendolyn Wu • Oct. 2, 2024 -
Retrieved from ASCO/Luke Franke 2024 on September 30, 2024
The top biopharma conferences remaining in 2025
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch the rest of 2025.
By BioPharma Dive staff • Updated June 30, 2025 -
Getty Images
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.
By BioPharma Dive staff • Oct. 1, 2024 -
Getty Images
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.”
By Gwendolyn Wu • Oct. 1, 2024 -
Getty Images
Aktis raises $175M to fuel radiopharma drug development
Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.
By Delilah Alvarado • Sept. 30, 2024 -
Getty Images
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.
By BioPharma Dive staff • Sept. 27, 2024 -
Getty Images
Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
By Jacob Bell • Updated Sept. 26, 2024 -
Getty Images
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science
Despite a restrictive funding climate, the startup creator is “in the ‘taking lots of risk’ mode,” said co-founder and managing director Robert Nelsen.
By Gwendolyn Wu • Sept. 26, 2024 -
Michael M. Santiago via Getty Images
BioAge prices $198M IPO, validating pivot to obesity drug research
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
By Gwendolyn Wu • Sept. 25, 2024 -
Getty Images
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers climbed.
By BioPharma Dive staff • Sept. 24, 2024 -
Permission granted by CRI
Q&AWant better cancer treatments? Make biopharma more like Silicon Valley
In an interview with PharmaVoice, Alicia Zhou, the new head of the nonprofit Cancer Research Institute, expressed a desire to foster deeper partnerships between scientists and the pharmaceutical industry.
By Michael Gibney • Sept. 24, 2024 -
Permission granted by Biogen
Biogen, UCB get the lupus data they’ve waited two decades for
The companies now plan on starting this year another large study of their medicine, dapirolizumab pegol, in the hopes that they can confirm its safety and effectiveness to drug regulators.
By Jacob Bell • Sept. 24, 2024 -
Courtesy of Biohaven Ltd.
After setback, Biohaven to seek approval of neurological disorder drug
With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.
By Jacob Bell • Sept. 23, 2024 -
Canva/ alexanders-images
Sponsored by PanalgoData advancements are finally unlocking drug safety during pregnancy
Dr. Meg Richards from Panalgo discusses how real-world data is unlocking advancements in drug safety during pregnancy.
By Meg Richards, PhD, MPH, Executive Director, Strategic Solutions & Consulting Services, Panalgo • Sept. 23, 2024 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines
The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said CEO Emmanuel Hanon.
By Delilah Alvarado • Sept. 23, 2024 -
Getty Images
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
By BioPharma Dive staff • Sept. 20, 2024 -
Courtesy of Roche
Roche’s Xofluza reduces flu transmission in Phase 3 study
According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.
By Delilah Alvarado • Sept. 19, 2024 -
Kimberly White/Getty Images via Getty Images
23andMe’s independent board directors resign
In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future.
By Ricky Zipp • Sept. 19, 2024
Previous
